vTv Therapeutics Inc.

NASDAQ:VTVT

Biotechnology

Healthcare
$16.23 +1.47%

+$0.50 today

Market cap
$64.17M
Beta
0.27
P/E (TTM)
128.7
EPS (TTM)
$0.27
52W Low $14.00High $44.00

Volume 0.02M

Average 0.05M

VTVT Interest Expense

Cost of servicing the company's debt during the period.

vTv Therapeutics Inc.NASDAQ: VTVT

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $6K. Over 3 fiscal years it compounded at -26.3% a year.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$6K— YoY
LTMMar 2026
$6K— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-26.3%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
6K USD
Year-over-year change
—
4-year CAGR
-15.9%

Interest Expense vs competitors

How VTVT compares with its peers on the latest reported figures

  • VTVT's LTM Mar 2026 interest expense of $6K is the 7th highest of the 9 companies compared; the peer median is $520.75K.
  • Interest expense amounts to 0.0% of revenue for VTVT, versus a peer median of 30.6%.
VTVT Competitors Peer median
Interest Expense for VTVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$9.57M -28.8%-13.9%14.5%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$4.55M -10.3%—21.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$904K +6.5%—39.4%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$728K +195.9%-40.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$313.51K —-42.5%94.1%
OSTXOS Therapies IncorporatedLTM Mar 2026$75.34K -93.8%——
VTVTvTv Therapeutics Inc.LTM Mar 2026$6K —-26.3%0.0%
INKTMiNK Therapeutics, Inc.LTM Mar 2026$0 ———
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding VTVT) $520.75K-10.3%-40.2%30.6%

Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.01M2.02M01.02M0
Cost of Revenue00000
Gross Profit4.01M2.02M01.02M0
Gross Margin100.0%100.0%—100.0%—
Research & Development13.32M12.36M13.6M11.55M17.86M
Selling, General & Admin12.34M12.2M11.91M13.65M14.95M
Operating Expenses25.67M24.56M25.5M25.2M32.81M
Depreciation & Amortization89K92K90K89K16K
EBITDA(17.52M)(24.77M)(25.86M)(22.52M)(31.06M)
EBITDA Margin-437.3%-1227.3%—-2214.0%—
Operating Income(21.66M)(22.54M)(25.5M)(24.18M)(32.81M)
Operating Margin-540.9%-1116.9%—-2377.6%—
Interest Income1K352K472K1.57M1.87M
Interest Expense12K15K13K06K
Other Income / Expenses4.05M(2.33M)(464K)1.58M1.73M
Income Before Tax(17.62M)(24.87M)(25.97M)(22.61M)(31.08M)
Pre-Tax Margin-439.9%-1232.6%—-2222.7%—
Income Tax Expense115K200K0100K0
Net Income(12.99M)(19.16M)(20.25M)(18.46M)(26.97M)
Net Margin-324.3%-949.7%—-1815.3%—
EPS (Basic)(8.29)(9.98)(9.71)(3.20)(3.20)
EPS (Diluted)(8.29)(9.98)(9.71)(3.20)(3.20)
Weighted Avg Shares1.57M1.92M2.08M5.77M8.42M
Weighted Avg Shares (Diluted)1.57M1.92M2.08M5.77M8.42M

vTv Therapeutics Inc.

NASDAQ:VTVT

Intrinsic Alpha fair value

Locked

Current Price

$16.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.